FDA approves ‘high-concentration, citrate-free’ Yuflyma as ninth Humira biosimilar

The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.Yuflyma (adalimumab-aaty, Celltrion USA) is a high-concentration (100 mg/mL), citrate-free biosimilar to the world’s top-selling Humira (adalimumab, AbbVie), approved for patients with adult Crohn’s disease, ulcerative colitis, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis andRead More